Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone

Table 6

6-month and 12-month PFS.

	6 months	12 months
Control group (n = 40)	32 (80.00)	27 (67.5%)
Study group (n = 40)	35 (87.5%)	31 (77.5%)
χ^2	0.827	1.003
	0.363	0.317